Actively Recruiting
Evaluating Visugromab With Pembrolizumab, Pemetrexed, and Carboplatin in First-Line Treatment of Metastatic Non-Squamous NSCLC A Randomized, Placebo-Controlled Phase 2b Trial
Led by CatalYm GmbH · Updated on 2026-10-19
107
Participants Needed
51
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Visugromab, an anti GDF-15 antibody, combined with immunochemotherapy in treating adults with newly diagnosed metastatic non-squamous non-small cell lung cancer NSCLC. This Phase 2b randomized, double-blind, placebo-controlled study aims to explore the safety and effectiveness of Visugromab plus standard immunochemotherapy compared to placebo with immunochemotherapy. The trial includes a safety-run-in phase followed by randomized treatment arms to gather preliminary efficacy and safety data.
CONDITIONS
Brief Title
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Research Team
F
Felix Lichtenegger, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here